In regard to the aspirin regiment, here is the link to the clinical trial which has started and is recruiting: https://clinicaltrials.gov/ct2/show/NCT03079999
However, the ability of aspirin to prevent AN growth was only seen in one study and other groups have tried and failed to confirm this result. Below is the result of a recently published paper that found no correlation:
Aspirin does not prevent growth of vestibular schwannomas: A case-control study.
MacKeith S1, Wasson J1, Baker C1, Guilfoyle M2, John D1, Donnelly N1, Mannion R2, Jefferies S3, Axon P1, Tysome JR1.
To determine if aspirin intake is associated with reduced growth of vestibular schwannomas (VS). To determine the prevalence of contraindications to regular aspirin in patients with VS.
Retrospective, observational case-control study.
The study utilized a postal questionnaire and telephone interviews to determine aspirin exposure. Propensity score matching was used to control for age, sex, and tumor size. Cases were defined as patients with VS proven to have grown on serial magnetic resonance imaging (MRI). Controls were defined as patient with VS stable on serial MRI. Prevalence of regular aspirin use was compared in patients with growing VS versus stable VS. Absolute and relative contraindications to aspirin intake were recorded.
Six hundred fifty-three patients with VS were contacted, and responses were received by 67% (220 cases and 217 controls). The mean tumor size was 11.3 mm (9.0 mm and 13.3 mm in controls and cases, respectively). Aspirin exposure was more common in stable VS than growing VS (22.1% vs. 17.3%). However, following matching to control for covariates, aspirin was not found to be associated with VS stability (P = .475). Multiple logistic regression (analysis of variance) found tumor size to be the only factor strongly associated with tumor growth (P < .0001). Ninety-two percent of patients were able to take aspirin, with the majority being at low risk of complications from regular use.
This study aimed to examine the relationship between aspirin intake and VS stability. In contrast to previous reports, after controlling for covariates, the findings do not demonstrate an association. Only tumor size at diagnosis appears predictive of risk of VS growth.
So while taking a daily aspirin may be beneficial to the heart, I don't believe it will prove to be of much help in controlling AN growth.